A Phase 2 interventional study of TQH2929 Injections and TQH2929 Placebo in Generalized Pustular Psoriasis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 31 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.
1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.
This study's enrollment of 36 is below the median of 70 across 1,447 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 313 studies on the registry; 75 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intravenous infusion, single dose
Drug: TQH2929 Injections
Intravenous infusion, single dose
Drug: TQH2929 Placebo
TQH2929 is a humanized monoclonal antibody that interfering with the signal cascade.
Placebo contains no active substance.
Percentage of patients with a score of 0 for the pustule subterm
Percentage of patients with a Physician's Global Assessment of Generalized Pustular Psoriasis (GPPGA) pustular subitem of 0 (no visible pustules) at week 1 among all enrolled patients.
Time frame: 1 week
Percentage of patients with a Generalized Pustular Psoriasis Physician Global Assessment(GPPGA) total score of 0 or 1
Percentage of patients with a total Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 (clear) or 1 (almost clear) at weeks 1 and 4.
Time frame: 1 week and 4 weeks
Percentage change from baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) total score
Percentage change from baseline in the total score of generalized pustular psoriasis area and severity index (GPPASI) at week 1 and week 4.
Time frame: 1 week and 4 weeks
Change from baseline in Generalized Pustular Psoriasis Area and Severity Index(GPPASI) total score
Change from baseline in Generalized Pustular Psoriasis Area and Severity Index(GPPAS) total score at week 1 and week 4. If lower than the baseline score, indicate a certain degree of disease relief; conversely, if higher, it indicates an aggravation of the disease symptoms.
Time frame: 1 week and 4 weeks
Percentage of patients with Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 50
Percentage of patients who achieved Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 50 at week 1 and week 4.
Time frame: 1 week and 4 weeks
Percentage of patients with Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 75
Percentage of patients who achieved Generalized Pustular Psoriasis Area and Severity Index(GPPASI) 75 at week 1 and week 4
Time frame: 1 week and 4 weeks
Percentage of patients with pustule subterm achieving a score of 0
Percentage of patients with Generalized Pustular Psoriasis Physician Global Assessment(GPPGA) pustule subterm achieving a score of 0 (no visible pustules) at week 4.
Time frame: 4 weeks
Change from baseline in Psoriasis Symptom Scale (PSS) score
Change from baseline in Psoriasis Symptom Scale (PSS) score at week 4
Time frame: 4 weeks
Change from baseline in disease life quality index (DLQI)
Change from baseline in skin disease life quality index (DLQI) at week 4. If lower than the baseline score, indicate a certain degree of disease relief; conversely, if higher, it indicates an aggravation of the disease symptoms.
Time frame: 4 weeks
Adverse Drug Event (AE)
Any untoward medical occurrence of a subject following drug treatment or exposure to an experimental factor, whether or not causally related to treatment or exposure.
Time frame: 113 days or 169 days
Serious Adverse Event (SAE)
An event that occurs in the course of a clinical trial that results in the death of a subject or patient, serious deterioration in health, hospitalization or prolongation of hospitalization, permanent disability or loss of function, or serious consequences such as birth defects or birth defects.
Time frame: 113 days or 169 days
Treatment-Emergent Adverse Events (TEAES)
Adverse events that occur during treatment, including from the start of treatment to a certain period of time after the end of treatment, may be directly or indirectly related to treatment.
Time frame: 113 days or 169 days
Abnormal clinical laboratory examination indicators
Any laboratory abnormalities that occur during the test.
Time frame: 113 days or 169 days
Time of maximum concentration (Tmax)
It refers to the time it takes for the human blood concentration curve to reach the highest concentration (peak concentration) after a single dose, measured in hours or minutes.
Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Maximum Concentration (Cmax)
The highest blood concentration reached after the drug is absorbed in the body.
Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Area Under the Curve (AUC)
It refers to the area covered by the concentration of a drug in the blood under the curve of changes over time.
Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Apparent Volume of Distribution(Vd/F)
When the drug reaches dynamic equilibrium in the body, the ratio of the amount of drug in the body to the blood concentration is called the apparent volume of distribution.
Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Apparent Clearance (CL/F)
The sum of drug clearance rates of liver and kidney, etc.
Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Plasma half-life time (t1/2)
The time it takes for the concentration of the drug in the plasma to drop by half.
Time frame: 1 hour pre-dose on day 1, immediately post dose, 1, 6, 24, 48, 168, 336, 504, 672, 1344, 2016, 2688 hours post dose. Day 8 Immediately after the end of salvage therapy administration, 1, 6, 24, 48 hours post dose
Anti-drug antibody (ADA)
Incidence of anti-drug antibodies (ADA) in subjects.
Time frame: Through study completion, an average of half a year
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.